Research Paper
Business Wire: Epizyme to Present New Scientific Data on the Role of HMT Inhibitors in Cancer
November 4, 2015
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, will present data from 11 accepted abstracts on the role of histone methyltransferase (HMT) inhibition in human cancers at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Mass., November 5 – 9, […]
Asian Pacific Journal of Cancer Prevention: Mutation Screening and Association Study of the Folylpolyglutamate Synthetase (FPGS) Gene with Susceptibility to Childhood Acute Lymphoblastic Leukemia
November 1, 2015
Duangjai Piwkham 1, Teerapong Siriboonpiputtana, Joke Beuten, Samart Pakakasama, Jonathan Al Gelfond, Karan Paisooksantivatana, Gail E Tomlinson, Budsaba Rerkamnuaychoke Abstract Background: Folylpolyglutamate synthetase (FPGS), an important enzyme in the folate metabolic pathway, plays a central role in the intracellular accumulation of folate and antifolate in several mammalian cell types. Loss of FPGS activity results in decreased cellular levels of antifolates and consequently to polyglutamatable […]
PNAS: Proline-, glutamic acid-, and leucine-rich protein 1 mediates estrogen rapid signaling and neuroprotection in the brain
November 1, 2015
Gangadhara R. Sareddy, Quanguang Zhang, Ruimin Wang, Erin Scott, Yi Zou, Jason C. O’Connor, Yidong Chen, Yan Dong, Ratna K. Vadlamudi, and Darrell Brann Abstract 17-β estradiol (E2) has been implicated as neuroprotective in a variety of neurodegenerative disorders. However, the underlying mechanism remains unknown. Here, we provide genetic evidence, using forebrain-specific knockout (FBKO) mice, that proline-, glutamic acid-, and leucine-rich protein 1 (PELP1), […]
Oncotarget: An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype
October 23, 2015
Ming-Kai Chuang1,*, Yu-Chiao Chiu2,5,*, Wen-Chien Chou1,3, Hsin-An Hou3, Mei-Hsuan Tseng3, Yi-Yi Kuo1,3, Yidong Chen5,6, Eric Y. Chuang2,4, Hwei-Fang Tien3 ABSTRACT Although clinical features, cytogenetics, and mutations are widely used to predict prognosis in patients with acute myeloid leukemia (AML), further refinement of risk stratification is necessary for optimal treatment, especially in cytogenetically normal (CN) patients. […]
ASCI Post: Children’s Hospital of Philadelphia Is a Founding Member of the New Pediatric Preclinical Testing Consortium (Houghton mention)
October 10, 2015
Addressing the relatively small number of new cancer drugs for children, a selective group of leading research centers is joining a new federally funded research consortium aimed at bringing scientific rigor and a concentrated effort to identifying new drug candidates for pediatric clinical trials. The Children’s Hospital of Philadelphia (CHOP) and four other high-profile oncology […]
Pediatric Blood & Cancer: Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma
October 1, 2015
Adam Studebaker 1, Kathryn Bondra 2, Star Seum 2, Changxian Shen 1, Doris A Phelps 1, Christopher Chronowski 2, Justin Leasure 2, Paul D Smith 3, Raushan T Kurmasheva 1, Xiaokui Mo 4, Maryam Fouladi 5, Peter J Houghton 1 Abstract Purpose: Curative therapy for childhood glioma presents challenges when complete resection is not possible. Patients with recurrent low-grade tumors or anaplastic astrocytoma may receive radiation treatment; however, the long-term sequelae from radiation treatment can be severe. As many […]
NCI PPTC: Sarcoma and Renal Tumor Research Program
September 1, 2015
Dr. Peter Houghton, Dr. Raushan Kurmasheva (Co-Investigator) Dr. Houghton is the Director of the Greehey Children’s Cancer Research Institute, which has as its mission to advance scientific knowledge relevant to childhood cancer and to accelerate the translation of knowledge into novel therapies. Dr. Houghton has been a leader in evaluating experimental agents using childhood […]
Pediatric Blood & Cancer: Radiation therapy may increase metastatic potential in alveolar rhabdomyosarcoma
September 1, 2015
Gary M Woods # 1, Kathryn Bondra # 2, Christopher Chronowski 2, Justin Leasure 2, Mamata Singh 2, Lauren Hensley 2, Timothy P Cripe 1, Arnab Chakravarti 2, Peter Houghton 1 Abstract Background: We previously determined that radiation could be safely administered using a mouse-flank in vivo model to both alveolar (Rh30) and embryonal (Rh18) rhabdomyosarcoma xenografts. Mice from both tumor lines in this experiment developed metastases, an event not previously described with these models. […]
Frontiers in Oncology: Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation
August 26, 2015
Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here, we discuss preclinical human tumor xenograft […]
Pathobiology of Aging & Age-related Diseases: Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy
August 24, 2015
Xiang Bai, Margaret Chia-Ying Wey, Elizabeth Fernandez, Matthew J. Hart, Jonathan Gelfond, Alex F. Bokov, Sheela Rani & Randy Strong Abstract Background Synucleinopathy is any of a group of age-related neurodegenerative disorders including Parkinson’s disease, multiple system atrophy, and dementia with Lewy Bodies, which is characterized by α-synuclein inclusions and parkinsonian motor deficits affecting millions of patients […]